Share this article on:

Low Incidence of Abacavir Hypersensitivity Reaction Among African Children Initiating Antiretroviral Therapy

Nahirya-Ntege, Patricia MD*; Musiime, Victor MD; Naidoo, Bethany DipIT; Bakeera-Kitaka, Sabrina MD§; Nathoo, Kusum MD; Munderi, Paula MD*; Mugyenyi, Peter MD; Kekitiinwa, Adeodata MD§; Bwakura-Dangarembizi, Mutsa F. MD; Crawley, Jane MDon Behalf of the ARROW Trial Team

The Pediatric Infectious Disease Journal: June 2011 - Volume 30 - Issue 6 - p 535-537
doi: 10.1097/INF.0b013e3182076864
Brief Reports

Hypersensitivity reactions are reported in approximately 5% of adults receiving abacavir, but there are few published data in children. Among 1150 African children receiving antiretroviral therapy in a randomized trial, suspected hypersensitivity reactions to abacavir were rare (0.3%; 95% CI, 0.01–0.9). Patients were managed successfully through the provision of clear guidelines and education of clinical staff, children, and their caregivers.

From the *MRC/UVRI Uganda Research Unit on AIDS, Uganda Virus Research Institute, Entebbe, Uganda; †Joint Clinical Research Centre, Kampala, Uganda; ‡Medical Research Council Clinical Trials Unit, London, United Kingdom; §Baylor-Uganda, Paediatric Infectious Diseases Clinic, Mulago Hospital, Kampala, Uganda; and ¶Department of Paediatrics and Child Health, University of Zimbabwe Medical School, Harare, Zimbabwe.

Accepted for publication November 17, 2010.

Supported by the UK Medical Research Council and the UK Department for International Development (DFID) (to the ARROW Trial). First-line drugs were donated by GlaxoSmithKline.

Address for correspondence: Jane Crawley, MD, Medical Research Council Clinical Trials Unit, 222 Euston Road, London NW1 2DA, United Kingdom. E-mail:

© 2011 Lippincott Williams & Wilkins, Inc.